Vistagen Strengthens Its Neurology Focused Pipeline With Pherin Pharma Acquisition

Vistagen Therapeutics Inc VTGN has agreed to acquire Pherin Pharmaceuticals Inc in an all-stock transaction of approximately 12.4 million shares.
Pherin is a clinical-stage drug development company focused on discovering and developing investigational pherine compounds for neuropsychiatric and neuroendocrine conditions.
Related: Independent Biostatisticians Recommend Vistagen Continue Late-Stage Anxiety Trial.
Vistagen is gaining full ownership of intellectual property rights to its two most advanced drug candidates, PH94B, currently in Phase 3 development for social anxiety disorder (SAD) and Phase 2 development for adjustment disorder with anxiety (AjDA), and PH10, in clinical development for major depressive disorder (MDD).
Vistagen will also expand its pipeline with three new early clinical-stage pherine product candidates: PH15 for cognition improvement, PH80 for migraine and hot flashes, and PH284 for appetite-related disorders.
Price Action: VTGN shares are up 3.13% at $0.11 on the last check Wednesday.